Clinical Trial Update: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease [Phase 3]

View source ↗

Summary

This completed Phase 3 trial tested an all-oral regimen of Ombitasvir/Paritaprevir/ritonavir with Dasabuvir, with or without Ribavirin, in adults with hepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Compensated Cirrhosis
• End-stage Renal Disease
• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Dasabuvir (dasabuvir)
• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-11-09